This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Cellectis's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.36. Cellectis's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-26), Cellectis's share price is $2.5056. Cellectis's Median PS Value is $0.00. Therefore, Cellectis's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Cellectis's Median PS Value or its related term are showing as below:
CLLS's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.64 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Cellectis Median PS Value Historical Data
The historical data trend for Cellectis's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cellectis's Median PS Value
For the Biotechnology subindustry, Cellectis's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectis's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectis's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Cellectis's Price-to-Median-PS-Value falls into.
Cellectis Median PS Value Calculation
Cellectis's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Cellectis's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectis (NAS:CLLS) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Cellectis's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
2.5056
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectis Median PS Value Related Terms
Thank you for viewing the detailed overview of Cellectis's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLLS has been successfully added to your 